Skip to main content
Clinical Trials/NCT03020563
NCT03020563
Withdrawn
Phase 4

Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?

University of Minnesota1 site in 1 countryAugust 23, 2017

Overview

Phase
Phase 4
Intervention
Liposomal Bupivacaine
Conditions
Clavicle Fracture
Sponsor
University of Minnesota
Locations
1
Primary Endpoint
Visual Analogue Pain Scale Averages between the two treatments
Status
Withdrawn
Last Updated
7 years ago

Overview

Brief Summary

To determine whether liposomal bupivacaine wound infiltration decreases pain scores and narcotic use when compared to bupivacaine alone after open reduction internal fixation of midshaft clavicle fractures.

Registry
clinicaltrials.gov
Start Date
August 23, 2017
End Date
January 1, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Mid-shaft Clavicle Fracture treated with ORIF

Exclusion Criteria

  • Unable to be contacted for 72 hours post surgery
  • Other concurrent surgical procedures
  • Chronic narcotic user

Arms & Interventions

Liposomal Bupivacaine

Time release Bupivacaine

Intervention: Liposomal Bupivacaine

Bupivacaine

Immediate Acting Bupivacaine

Intervention: Bupivacaine

Outcomes

Primary Outcomes

Visual Analogue Pain Scale Averages between the two treatments

Time Frame: 72 hours post surgery

Scale is based on 1-10 with 1 being the lowest pain and 10 being the highest pain.

Study Sites (1)

Loading locations...

Similar Trials